Gain Therapeutics (GANX) News
NASDAQ: GANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.9994-0.0506 (-4.82%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GANX news summary
We found 5 recent headlines mentioning Gain Therapeutics (GANX): 2 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, GANX is down 4.82% at $0.9994. The most recent story, "Gain Therapeutics, Inc. Reports Phase 1b Clinical Data for Rexaceract", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Gain Therapeutics headlines
- Gain Therapeutics, Inc. Reports Phase 1b Clinical Data for RexaceractGain Therapeutics, Inc. announced the presentation of clinical data from the Phase 1b clinical study of rexaceract. As of November 1, 2026, all 13 evaluable patients in the Phase 1b clinical study…Nasdaq
- Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression among the 13 evaluable participants who completed 12…GlobeNewswire
- Gain Therapeutics Q3 Loss Narrows(RTTNews) - Gain Therapeutics, Inc. (GANX) on Tuesday reported a narrower net loss for the third quarter of 2026 compared with the same period in 2025, as reduced research and development and general…Nasdaq
- Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateBETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…GlobeNewswire
- Gain Therapeutics, Inc. Appoints Jeanette Weidner as Vice President, Finance, Effective October 28, 2026Gain Therapeutics, Inc. appointed Jeanette Weidner as its Vice President, Finance, with an effective date of October 28, 2026. In this role, Ms. Weidner will also serve as the Company’s…NasdaqGANX, BF.B